Augmented cardiac formation of oxidatively-induced carbonylated proteins accompanies the increased functional severity of post-myocardial infarction heart failure in the setting of type 1 diabetes mellitus

Cardiovascular Pathology

Volumn 22, Issue 6, 2013, Pages 473-480

  Dennis, Kathleen E ^a   Hill, Salisha ^b   Rose, Kristie L ^b   Sampson, Uchechukwu K A ^a   Hill, Michael F ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carbonylation; Heart failure; Myocardial infarction; Oxidative stress; Type 1 diabetes mellitus

Indexed keywords

CARBONYL DERIVATIVE; GLUCOSE; MITOCHONDRIAL PROTEIN; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ECHOCARDIOGRAPHY; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MASS SPECTROMETRY; NONHUMAN; OXIDATIVE STRESS; POSTERIOR MYOCARDIAL INFARCTION; POSTMYOCARDIAL INFARCTION HEART FAILURE; PRIORITY JOURNAL; PROTEIN CARBONYLATION; RAT;

CARBONYLATION; HEART FAILURE; MYOCARDIAL INFARCTION; OXIDATIVE STRESS; TYPE 1 DIABETES MELLITUS;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; ENZYMES; FATTY ACIDS; HEART FAILURE; MITOCHONDRIA, HEART; MYOCARDIAL INFARCTION; MYOCARDIUM; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RATS; SEVERITY OF ILLNESS INDEX; SYSTOLE; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84893654088     PISSN: 10548807     EISSN: 18791336     Source Type: Journal    
DOI: 10.1016/j.carpath.2013.03.001     Document Type: Article

References (33)

1. Mukamal KJ, Nesto RW, Cohen MC, Muller JE, Maclure M, Sherwood JB, Mittleman MA. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care 2001;24:1422-7.
2. Woodfield SL, Lundergan CF, Reiner JS, Greenhouse SW, Thompson MA, Rohrbeck SC, Deychak Y, Simoons ML, Califf RM, Topol EJ, Ross AM. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 1996;28:1661-9.
3. Granger CB, Califf RM, Young S, Candela R, Samaha J, Worley S, Kereiakes DJ, Topol EJ. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 1993;21:920-5.
4. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
5. Solomon SD, St John Sutton M, Lamas GA, Plappert T, Rouleau JL, Skali H, Moye L, Braunwald E, Pfeffer MA. Survival And Ventricular Enlargement (SAVE) Investigators. Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation 2002;106:1251-5.
6. Aguilar D, Solomon SD, Køber L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O'Connor CM, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 2004;110:1572-8.
7. Stone PH, Muller JE, Hartwell T, York BJ, Rutherford JD, Parker CB, Turi ZG, Strauss HW, Willerson JT, Robertson T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 1989;14:49-57.
8. Barbash GI, White HD, Modan M, Van De Werf F. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. J Am Coll Cardiol 1993;22:707-13.
9. Becker RC, Terrin M, Ross R, Knatterud GL, Desvigne-Nickens P, Gore JM, Braunwald E. Comparison of clinical outcomes for women and men after acute myocardial infarction. The Thrombolysis in Myocardial infarction Investigators. Ann Intern Med 1994;120:638-45.
10. Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, Califf RM, Topol EJ. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-IInvestigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997;30:171-9.
11. Smith HM, Hamblin M, Hill MF. Greater propensity of diabetic myocardium for oxidative stress after myocardial infarction is associated with the development of heart failure. J Mol Cell Cardiol 2005;39:657-65.
12. Banfi C, Brioschi M, Barcella S, Veglia F, Biglioli P, Tremoli E, Agostoni P. Oxidized proteins in plasma of patients with heart failure: role in endothelial damage. Eur J Heart Fail 2008;10:244-51.
13. Madian AG, Regnier FE. Proteomic identification of carbonylated proteins and their oxidation sites. J Proteome Res 2010;9:3766-80.
14. Baraibar MA, Hyzewicz J, Rogowska-Wrzesinska A, Ladouce R, Roepstorff P, Mouly V, Friguet B. Oxidative stress-induced proteome alterations target different cellular pathways in human myoblasts. Free Radic Biol Med 2011;51:1522-32.
15. Wang Z, Hill S, Luther JM, Hachey DL, Schey KL. Proteomic analysis of urine exosomes by multidimensional protein identification technology (MudPIT). Proteomics 2012;12:329-38.
16. Ahmed N, Babaei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ. Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 2005;48:1590-603.
17. Rabilloud T, Heller M, Gasnier F, Luche S, Rey C, Aebersold R, Benahmed M, Louisot P, Lunardi J. Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. J Biol Chem 2002;277:19396-401.
18. Bäcklund T, Palojoki E, Saraste A, Eriksson A, Finckenberg P, Kytö V, Lakkisto P, Mervaala E, Voipio-Pulkki LM, Laine M, Tikkanen I. Sustained cardiomyocyte apoptosis and left ventricular remodelling after myocardial infarction in experimental diabetes. Diabetologia 2004;47:325-30.
19. Shiomi T, Tsutsui H, Ikeuchi M, Matsusaka H, Hayashidani S, Suematsu N, Wen J, Kubota T, Takeshita A. Streptozotocin-induced hyperglycemia exacerbates left ventricular remodeling and failure after experimental myocardial infarction. J Am Coll Cardiol 2003;42:165-72.
20. Song GY, Wu YJ, Yang YJ, Li JJ, Zhang HL, Pei HJ, Zhao ZY, Zeng ZH, Hui RT. The accelerated post-infarction progression of cardiac remodelling is associated with genetic changes in an untreated streptozotocin-induced diabetic rat model. Eur J Heart Fail 2009;1:911-21.
21. Hamblin M, Friedman DB, Hill S, Caprioli RM, Smith HM, Hill MF. Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. J Mol Cell Cardiol 2007;42:884-95.
22. Hamblin M, Smith HM, Hill MF. Dietary supplementation with vitamin E ameliorates cardiac failure in type I diabetic cardiomyopathy by suppressing myocardial generation of 8-iso-prostaglandin F2alpha and oxidized glutathione. J Card Fail 2007;13:884-92.
23. Maeda CY, Fernandes TG, Timm HB, Irigoyen MC. Autonomic dysfunction in shortterm experimental diabetes. Hypertension 1995;26:1100-4.
24. Hicks KK, Seifen E, Stimers JR, Kennedy RH. Effects of streptozotocin-induced diabetes on heart rate, blood pressure and cardiac autonomic nervous control. J Auton Nerv Syst 1998;69:21-30.
25. Sakamoto J, Barr RL, Kavanagh KM, Lopaschuk GD. Contribution of malonyl-CoA decarboxylase to the high fatty acid oxidation rates seen in the diabetic heart. Am J Physiol Heart Circ Physiol 2000;278:H1196-204.
26. Nagareddy PR, Xia Z, MacLeod KM, McNeill JH. N-acetylcysteine prevents nitrosative stress-associated depression of blood pressure and heart rate in streptozotocin diabetic rats. J Cardiovasc Pharmacol 2006;47:513-20.
27. Borges GR, De Oliveira M, Salgado HC, Fazan R. Myocardial performance in conscious streptozotocin diabetic rats. Cardiovasc Diabetol 2006;5:26.
28. Banyasz T, Kalapos I, Kelemen SZ, Kovacs T. Changes in cardiac contractility in IDDM and NIDDM diabetic rats. Gen Physiol Biophys 1996;15:357-69.
29. Banyasz T, Kovacs T. Altered [3H]ouabain binding to cardiac muscle in insulin dependent and non-insulin-dependent diabetic rats. Exp Physiol 1998;83:65-76.
30. Retnakaran R, Zinman B. Type 1 diabetes, hyperglycaemia, and the heart. Lancet 2008;371:1790-9.
31. Adolphe AB, Glasofer ED, Troetel WM, Weiss AJ, Manthei RW. Preliminary pharmacokinetics of streptozotocin, an antineoplastic antibiotic. J Clin Pharmacol 1977;17:379-88.
32. Fein FS, Strobeck JE, Malhotra A, Scheuer J, Sonnenblick EH. Reversibility of diabetic cardiomyopathy with insulin in rats. Circ Res 1981;49:1251-61.
33. Pierce GN, Kutryk MJ, Dhalla NS. Alterations in Ca2+ binding by and composition of the cardiac sarcolemmal membrane inchronic diabetes. Proc Natl Acad Sci U S A 1983;80:5412-6.